Key points
- The proteome is the complete set of proteins in a cell, tissue, or organism. Unlike the genome, it changes constantly.
- Most drugs act on proteins: one analysis identified 667 human proteins targeted by FDA-approved drugs.
- Proteins are measured mainly by mass spectrometry or by affinity-based methods that use antibodies or other binding molecules.
- Large studies now combine proteomics with genetics. One measured 2,923 plasma proteins in 54,219 UK Biobank participants.
- In drug development, proteomics helps validate targets, discover biomarkers, and show whether a drug is affecting its target.
Genes contain instructions, but proteins do most of the work. They form the structures of cells, carry signals, speed up chemical reactions, and fight infections. Proteomics is the large-scale study of proteins, and since nearly every drug works by acting on a protein, it is one of the most directly useful "omics" fields for drug development.
The proteome
The proteome is the complete set of proteins present in a cell, tissue, or organism at a given time. It differs from the genome in important ways:
| Genome | Proteome | |
|---|---|---|
| What it is | All of an organism's DNA | All of the proteins being made |
| Stability | Essentially the same in every cell, for life | Differs between tissues and changes with time, health, diet, and drugs |
| Complexity | About 19,900 protein-coding genes in humans | Far more distinct protein forms, because one gene can produce several proteins and proteins are chemically modified after they are made |
The National Human Genome Research Institute notes that each human gene codes for an average of about three proteins. Proteins are then further modified, for example by attaching phosphate or sugar groups, which can switch their activity on or off.
Why proteins matter for drug development
Most drugs act on proteins: an enzyme they block, a receptor they activate, or a signaling molecule they neutralize. A 2017 analysis in Nature Reviews Drug Discovery cataloged the molecular targets of 1,578 FDA-approved drugs and identified 667 human proteins targeted by drugs for human disease.
Measuring proteins helps answer questions that DNA alone cannot:
- Is the target protein actually present in the diseased tissue?
- Is it more abundant, or more active, in patients than in healthy people?
- Does the experimental drug change the protein, or its downstream activity, in patients?
How proteins are measured
Mass spectrometry
Mass spectrometry measures molecules by their mass. In a typical proteomics experiment:
- Proteins are extracted from a sample and cut into smaller pieces, called peptides, using enzymes.
- The peptides are separated and fed into a mass spectrometer, which measures their mass with very high precision.
- Software matches the measured peptides against databases of known protein sequences to identify which proteins were present and estimate how much of each.
Mass spectrometry can identify proteins without knowing in advance what to look for, and it can detect chemical modifications.
Affinity-based methods
Affinity methods use molecules that bind specific proteins, such as antibodies or engineered DNA-like molecules called aptamers. These methods can measure thousands of predefined proteins in small blood samples at high throughput. That makes them well suited to large population studies, though they can only measure the proteins their binding reagents were designed for.
| Method | Strengths | Limitations |
|---|---|---|
| Mass spectrometry | Unbiased discovery; detects modifications; high specificity | Lower throughput; less sensitive for very low-abundance proteins in blood |
| Affinity-based | High throughput; small samples; very sensitive | Limited to predefined proteins; depends on binding-reagent specificity |
Proteomics meets genomics
Some of the most powerful recent work combines protein measurements with genetic data. By finding genetic variants that change the levels of specific proteins, researchers can test whether a protein plays a causal role in disease, rather than merely being associated with it.
The UK Biobank Pharma Proteomics Project, a consortium of pharmaceutical companies, measured 2,923 plasma proteins in 54,219 UK Biobank participants. Its 2023 report in Nature identified 14,287 primary genetic associations with protein levels, 81% of which had not been described before. The authors highlighted how such data can extend the genetic evidence for drug targets, using PCSK9 as an example. This links directly to the evidence that genetically supported drug targets succeed more often. See What Is Genomics?
Uses in drug development
| Use | Example |
|---|---|
| Target discovery and validation | Identifying proteins that are elevated in disease and genetically linked to it |
| Biomarker discovery | Finding proteins whose levels predict disease, prognosis, or response to treatment |
| Pharmacodynamic biomarkers | Showing that a drug is reaching and affecting its target in patients |
| Safety | Detecting early protein signals of organ injury |
| Patient selection | Identifying patients whose disease is driven by a particular protein pathway |
Biomarkers discovered through proteomics still have to be validated before they can be relied on in clinical decisions or as trial endpoints. The FDA-NIH BEST resource sets out the categories of biomarkers and the evidence each requires.
Limitations
- Dynamic range. Blood contains a few extremely abundant proteins and thousands of rare ones, which makes the rare ones hard to measure.
- Measurement differences. Different platforms can give different results for the same protein, so findings need confirmation with an independent method.
- Snapshots in time. Protein levels change from hour to hour, so a single measurement may not represent a person's typical state.
- Association is not causation. A protein that is elevated in a disease may be a consequence of the disease rather than a cause, which is why combining proteomics with genetics is so valuable.
Where to explore protein data
The Human Protein Atlas is a freely available resource that maps where human proteins are found across tissues and cells. It is widely used to check whether a potential drug target is present in the tissue a drug is meant to treat, and where else it might cause side effects.
Sources
- Santos R, et al. A comprehensive map of molecular drug targets. Nature Reviews Drug Discovery. 2017;16(1):19–34.Peer-reviewed
- Sun BB, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329–338.Peer-reviewed
- National Human Genome Research Institute. A Brief Guide to Genomics.Regulator
- The Human Protein Atlas.Registry
- FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource.Regulator
This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.